Details for New Drug Application (NDA): 065129
NDA 065129 describes SUPRAX, which is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms, and is included in eight NDAs. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the SUPRAX profile page.
The generic ingredient in SUPRAX is cefixime. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in SUPRAX is cefixime. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 065129
| Tradename: | SUPRAX |
| Applicant: | Lupin Pharms |
| Ingredient: | cefixime |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065129
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SUPRAX | cefixime | FOR SUSPENSION;ORAL | 065129 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-405 | 68180-405-01 | 50 mL in 1 BOTTLE (68180-405-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 100MG/5ML | ||||
| Approval Date: | Feb 23, 2004 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
